These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Ceftriaxone: a summary of in vitro antibacterial qualities including recommendations for susceptibility tests with 30-micrograms disks.
    Author: Jones RN, Barry AL, Thornsberry C.
    Journal: Diagn Microbiol Infect Dis; 1983 Dec; 1(4):295-311. PubMed ID: 6321093.
    Abstract:
    The new aminothiazoyl-cephalosporin, ceftriaxone (Ro 13-9904), was found to have excellent inhibitory activity against the Enterobacteriaceae (minimum inhibitory concentration needed to inhibit 50% of isolates (MIC50) less than or equal to 0.004-0.5 microgram/ml, Haemophilus influenzae (MIC50 less than or equal to 0.004 micrograms/ml), Neisseria species (MIC50 less than or equal to 0.001 microgram/ml), pneumococci (MIC50 0.25 micrograms/ml), Staphylococcus aureus (MIC50 2.0 micrograms/ml), and Streptococcus pyogenes (MIC50 0.015 micrograms/ml). Ceftriaxone was less effective against Acinetobacter species, Pseudomonas aeruginosa, and other Pseudomonas species (MIC50 8.0-16 micrograms/ml). Methicillin-resistant S. aureus and enterococci were not significantly inhibited by ceftriaxone. Ceftriaxone was very resistant to beta-lactamase hydrolysis, although the type IV cephalosporinase minimally destroyed the compound at 16.4-19.9% of the rates for cephaloridine. Type I cephalosporinases were inhibited by ceftriaxone and related enzyme-stable cephalosporins. Based on analysis of disk-MIC regression statistics, tentative recommendations for the disk test of the National Committee for Clinical Laboratory Standards are 21 mm or more = susceptible, 14-20 mm = moderately susceptible, and 13 mm or less = resistant. These criteria produce interpretive accuracy of more than 92%, with very rare major errors. Ceftriaxone was comparable to cefotaxime in spectrum and activity, thus allowing the use of the "spectrum-class" concept (for example, cefotaxime tests in vitro to predict ceftriaxone susceptibility, and vice versa).
    [Abstract] [Full Text] [Related] [New Search]